Minireviews
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107700
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107700
Table 1 Pre-treatment staging system
Stage
Specifics
PRETEXT/POST-TEXT IOnly one liver section is involved by the tumor
PRETEXT/POST-TEXT IITumor involves two contiguous sections of the liver
PRETEXT/POST-TEXT IIITumor involves three liver sections, or two non-contiguous sections
PRETEXT/POST-TEXT IVTumor involves all four liver sections
Table 2 Evan’s surgical stage
Stage
Specifics
IComplete gross resection with clear margins
IIGross total resection with microscopic residual disease at margin of resection
IIIGross total resection with nodal involvement or tumor spill or incomplete resection with gross residual intrahepatic disease
IVMetastatic disease with either complete or incomplete resection
Table 3 Risk stratification criteria for hepatoblastoma
Risk group
Stratification criteria
Very low riskPostoperative COG stage I with well-differentiated fetal histology
Low riskMeets any of the followingSerum AFP ≥ 100 ng/mL, PRETEXT stage I or II, and absence of high-risk features
Portal vein involvement (P+)
Inferior vena cava or hepatic vein involvement (V+)
Distant metastasis (M+)
Extrahepatic abdominal disease (E+)
Tumor rupture or intraperitoneal hemorrhage (H+)
Lymph node involvement (N+)
Postoperative COG stage I or II with non-pure fetal and non-small-cell undifferentiated histology
Intermediate riskMeets any of the followingPreoperative PRETEXT stage III
Postoperative COG stage I or II with small-cell undifferentiated histology
Postoperative COG stage III
High riskMeets any of the followingSerum AFP < 100 ng/mL
Preoperative PRETEXT stage IV
Postoperative COG stage IV
Portal vein (P+) or inferior vena cava/hepatic vein involvement (V+)